Godsey & Gibb Inc. Has $23.96 Million Stake in Stryker Co. (NYSE:SYK)

Godsey & Gibb Inc. reduced its holdings in Stryker Co. (NYSE:SYK) by 1.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 66,536 shares of the medical technology company’s stock after selling 724 shares during the quarter. Stryker accounts for about 2.4% of Godsey & Gibb Inc.’s investment portfolio, making the stock its 12th largest holding. Godsey & Gibb Inc.’s holdings in Stryker were worth $23,956,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of SYK. Dunhill Financial LLC raised its holdings in shares of Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares during the period. Centennial Bank AR increased its holdings in Stryker by 106.7% during the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after purchasing an additional 48 shares in the last quarter. Darwin Wealth Management LLC acquired a new stake in shares of Stryker in the 3rd quarter valued at about $36,000. Hara Capital LLC bought a new stake in shares of Stryker in the third quarter valued at about $42,000. Finally, HBW Advisory Services LLC acquired a new position in shares of Stryker during the third quarter worth about $42,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 5.50% of the stock is currently owned by corporate insiders.

Stryker Trading Up 1.5 %

Shares of Stryker stock opened at $368.09 on Thursday. Stryker Co. has a 1 year low of $307.23 and a 1 year high of $398.20. The company has a market capitalization of $140.32 billion, a price-to-earnings ratio of 39.45, a P/E/G ratio of 2.51 and a beta of 0.95. The business has a fifty day simple moving average of $375.13 and a two-hundred day simple moving average of $358.25. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.77 by $0.10. The business had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. Stryker’s revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.46 EPS. Research analysts forecast that Stryker Co. will post 12.06 EPS for the current year.

Stryker Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.84 dividend. The ex-dividend date is Tuesday, December 31st. This is an increase from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a yield of 0.91%. Stryker’s payout ratio is 36.01%.

Analysts Set New Price Targets

Several research firms have commented on SYK. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $370.00 to $445.00 in a research note on Monday, December 2nd. Citigroup lifted their price objective on shares of Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. JPMorgan Chase & Co. increased their target price on shares of Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. UBS Group lifted their price target on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Finally, Evercore ISI increased their price objective on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $405.80.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.